Liquid Testolone (RAD 140) – 15MG/ML

High Quality Liquid RAD 140 For Sale

RAD 140, also known as Testolone, is one of several selective androgen receptor modulators (SARMs) that was initially developed as a potential alternative to testosterone replacement therapy. It should not be confused with it’s esterified form, RAD 150, also known as TLB 150.

RAD140 binds to the androgen receptors (AR) in a selective manner and does not produce the full range of androgenic effects as similar substances like testosterone, DHT, or anabolic steroids.

High AR Binding Affinity of RAD 140

RAD140 demonstrated excellent affinity for the AR (Ki = 7 nM), higher even than DHT and most anabolic steroids. For reference, the the affinity for the androgen receptor (AR) for Testosterone in a recent preclinical model was 29 nM, and 10 nM for DHT.

Unlike testosterone and most other AR mediated anabolic agents, Testolone is orally bioavailable so it does not require injection for proper absorption and it is considered by many researchers to be one of the best SARMs for bulking and adding lean body mass.

Testolone is a fairly recent addition to the list of SARMs for sale; it was developed in 2010 as a possible treatment for osteoporosis and muscle gains. More recent testing performed on rats and primates as well as clinical trials have indicated that it may provide additional benefits as well. 

RAD 140 and Muscle Growth

A study on young male cynomolgus monkeys investigated the anabolic effects of 28 days of RAD140 at a dosage of 0.01mg/kg, 0.1mg/kg, and 1mg/kg per day. A mean weight gain of 10% was observed in both the 0.1mg/kg/day group and the 1mg/kg/day group, indicating a quantity response curve that leveled off and provided no additional benefit with higher quantities.

There was no consistent effect on body fat mass in either group, however muscle mass increased in the 0.1 and 1mg/kg/day groups. No significant increases in liver enzymes or prostate weight were reported in either group suggesting a high level of selectivity for androgen receptors in muscle tissue.

RAD140 and Neuroprotection

Androgens have shown clinical significance in preventing neuronal apoptosis and improving cognitive function in Alzheimer’s Disease (AD), primarily through a nongenomic mechanism of the Androgen Receptor (AR). Rapid phosphoinositide 3-kinase/Akt signaling, activated by androgens, regulates the expression of proteins linked to apoptosis such as bax, seladin 1, survivin, XIAP, and bcl-xl.

Androgens can also maintain the integrity of neurons and thus improve cognitive function. Studies have shown that Aβ impairs synaptic structure and function of hippocampal neurons which is reversed by androgen administration resulting in improved cognitive performances in AD animal models. Although the underlying exact mechanisms are not yet fully understood, androgen’s action of inhibiting Aβ-induced apoptosis appears to play a role.

RAD 140 and Cellular Protection

A 2014 study investigated the neuroprotective effects of RAD140 on cultured neurons and male rats that were lesioned with kianate. The experiment included two parts – one in vitro involving cell cultures and another in vivo through animal testing.

Results from the in vitro study showed that RAD140 was able to prevent cell death and restore mitochondrial membrane potential, indicating that it could offer neuroprotection much like testosterone and other androgens investigated for these effects.

The in vivo experiment tested the efficacy of RAD140 on male rats with kainate-induced seizures and showed a significant reduction in seizure activity compared to controls. Overall, this study demonstrated that RAD140 is capable of offering neuroprotection both in vitro and in vivo, suggesting it may one day have a place in treating neurological disorders.

RAD 140 and Dementia

Another study on rats found that RAD140 had neuroprotective benefits of a kind that may prevent Alzheimer’s disease and similar disorders, and may be safer than conventional testosterone therapy The group treated with 3 mg/kg RAD140 was able to replicate the same level of muscle tissue growth as the group treated with 1 mg/kg Testosterone, with about half of the androgenic activity in the prostate.

RAD-140 and Breast Cancer

A 2017 study investigated the effects of RAD140 on breast cancer cells. The study evaluated the efficacy of RAD140 in inhibiting the growth of breast cancer cells that were positive for both androgen receptors (ARs) and estrogen receptors (ERs).

Results showed that in in vivo and in vitro models of AR/ER+ breast cancer, RAD140 was able to significantly reduce the growth and metastases of breast cancer cells without disrupting their cell cycle, indicating it could be a promising therapy for treating such cancers.

Moreover, the study also showed that RAD140 had distinct mechanisms of action from those of anti-estrogens and aromatase inhibitors, which suggests that it could provide an additional therapeutic approach to treating hormone-sensitive breast cancers.

Overall, this study suggests that RAD140 could be a potential option for AR/ER positive breast cancer but more data is needed to determine its safety relative to other methods utilized at this time.

RAD 140 Mechanism of Action

In Vitro, the RAD140 SARM has produced a wide array of effects including:

• Increased weight loss and body fat loss
• Increased lean muscle growth and protein synthesis
• Increased removal of beta amyloid plaques from the brain
• Increased protection against breast and prostate cancer
• Increased endurance

However, it must be understood that the Food and Drug Administration (FDA) has not confirmed any health effects of RAD 140 for human beings or approved it for human use, and the drug should be used for laboratory research use only. Anecdotal reports indicate a potential for testosterone suppression and other side effects in males from RAD 140 administration.

Side effects of RAD 140

While RAD140 and other SARMs do not cause androgenic side effects to the same extent as anabolic steroids like Testosterone, reports have revealed the potential for nausea, aggression, reduction in natural testosterone levels, or mild male pattern hair loss from the use of RAD 140. A single-member case report indicated drug-induced liver injury after 11 months of the use of an anti-depressant, as well as intermittent use of RAD 140 and LGD-4033.

The limitations of this study however are the fact that it includes only one test subject, 11 months of concurrent antidepressant use, the quality and quantity of SARMs used by the subject were not monitored, and additional comorbidities were not investigated.

Several case reports exist indicating the potential for selective androgen receptor modulators to contribute to liver injury but none involve a significant sample size or test controls to date. Like other SARMs, RAD 140 may trigger a negative feedback loop and a reduction in natural testosterone production and testicle size though further research is needed to determine the likelihood and severity of this occurrence.